Latest News
View More
The big interview: Cisco UK and Ireland CEO David Meads
Foreseeing a global pandemic is not in any business leader’s job description. But perhaps the most vital skill for today’s…
Latest News
View More
GSK begins Phase III RSV maternal candidate vaccine study
GlaxoSmithKline (GSK) has initiated dosing of patients in the Phase III clinical programme evaluating the safety and efficacy of its Respiratory Syncytial Virus (RSV) candidate…
Pfizer initiates dosing in Phase III haemophilia therapy trial
Pfizer has dosed the first participant in the Phase III BASIS study of the investigational therapy, marstacimab (PF-06741086), for treating people with severe haemophilia A…
Parexel’s EPCU Berlin and CTC North partner on clinical trial research
Parexel’s Early Phase Clinical Unit (EPCU) in Berlin, Germany has collaborated with Clinical Trial Center (CTC) North to increase the…
Boehringer and Icahn School begin enrolment in Covid-19 trial
The Icahn School of Medicine at Mount Sinai, Department of Medicine's Clinical Trials Office and Boehringer Ingelheim have enrolled the…
Innovent’s HCC therapy trial meets primary endpoints
Innovent Biologics has reported positive interim analysis results from Phase III ORIENT-32 study of anti-PD-1 antibody-based combination therapy versus sorafenib…
Eisai reports dose comparison data from Lenvima thyroid cancer trial
Eisai has reported results from the Phase II Study 211 of two doses of its orally available multiple receptor tyrosine…
Expert Commentary & Analysis
View MoreRegistration of head-to-head psoriatic arthritis clinical trial begins the battle for second place
On 17 November 2020, Novartis registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnson’s Stelara (ustekinumab). The 28-week study…
Increase of resumed trials slowing due to Covid-19 cases rising
Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of…
Brainstorm’s NurOwn fails Phase III trial, demonstrating the struggle to develop effective ALS treatment
On 17 November, Brainstorm Cell Therapeutics announced topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy, NurOwn, as its Phase III trial did not reach statistically significant…
Biogen’s aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed
by William Newton in Texas. Biogen antibody aducanumab, if FDA-approved for mild Alzheimer’s disease (AD), will likely face significant barriers to coverage. Questionable efficacy, a high cost of USD 50,000…